Bernie Sanders drew ire from Martin Shkreli, Turing Pharmaceutical's CEO famed for drug price gouging, when he "rejected" a $2,700 campaign donation.
Instead of accepting the money and Shkreli's endorsement, Sanders effectively rejected the donation and instead pledged a donation to a health clinic for the same amount.
Ever the mature businessman, Shkreli, who late last month defended the 5,000 percent price hike on Daraprim, took to Twitter to express his anger in a normal, healthy manner.
Since then, Shkreli has gone on a trolling Twitter ramage to express his extreme dislike for Sanders and fellow Democratic candidate Hillary Clinton.
And so on.
This latest trolling from Shkreli comes on the heels of reports earlier last week that the New York Attorney General's office is investigating Turing for raising the price of Daraprim from $13 per tablet to $750 per tablet. The investigation will determine if the price rise restricted access to Daraprim. Shkreli defended the price rise, saying that the money was necessary to fund further research into better treatments for toxoplasmosis, one disease Daraprim is commonly used to treat.
The price rise, however, was soundly criticized, as patients most likely to use Daraprim are those with weakened immune systems like HIV and cancer patients, and pregnant women. The new price also seemed especially egregious given that Daraprim was first developed 70 years ago and hasn't changed since. In addition, manufacturing costs for the pill are minor, leading critics to believe the price rise was unjustified.
In response to the backlash, Shkreli said that Turing would reduce the amount the price of the drug would be raised but the company has yet to follow through on a decrease.